🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Identification of Lesion Characteristics in Coronary Plaques Using Multimodality Intravascular Imaging and Novel Photon-counting CT in Stable Angina

Recruitingn/aAges 18 Years - 79 YearsAllQueen Mary University of London
NCT07864025 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Coronary artery disease, caused by the furring up of the heart arteries by atherosclerosis, is a major cause of death in the UK. Despite existing therapies, adverse cardiovascular events remains high, especially in patients who have already had a heart attack, as some of these patients have aggressive atherosclerotic disease. If we could identify these vulnerable patients, then in wider clinical practice in the future we might be able to treat them better with new therapies that can otherwise be expensive or come with a risk of side-effects. Traditionally, the assessment of atherosclerotic disease and the identification of the plaques that will cause heart attacks is performed using invasive imaging - imaging taken by passing a wire into the arteries of the heart that has a camera on its tip. Invasive imaging, however, can be used only in patients with symptoms and has risks. Photon coun

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Able and willing to give informed consent * Between ages 18-79 * Patients with a stable coronary syndrome that had recent PC-CTA showing at least one lesion requiring further evaluation with intravascular imaging or fractional flow reserve and is considered suitable for PCI under IVUS guidance Exclusion Criteria: * Unable to or unwilling to give informed consent * Age \>80 years * Recent acute coronary syndrome within \< 3 months * Renal failure (eGFR \<60ml/min/1.73m²) * History of previous coronary artery bypass surgery * Decompensated heart failure, or left ventricular ejection fraction ≤30% * Previous heart transplantation * Intravenous contrast allergy * Unable to receive treatment with aspirin, heparin, or thienopyridines * Anticipated life expectancy \<1 year * Pregnancy * Patient that requires surgical revascularisation * Extensive coronary artery disease (i.e. multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with NIRS-IVUS imaging
💊

What it tests

  • observational study
📍

Where

1 site
William Harvey Research Institute, Barts and The London, Queen Mary University of London
London, United Kingdom
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy